DK0663912T3 - Heterocykliske etherforbindelser til forstærkning af den kognitive funktion - Google Patents

Heterocykliske etherforbindelser til forstærkning af den kognitive funktion

Info

Publication number
DK0663912T3
DK0663912T3 DK93923826T DK93923826T DK0663912T3 DK 0663912 T3 DK0663912 T3 DK 0663912T3 DK 93923826 T DK93923826 T DK 93923826T DK 93923826 T DK93923826 T DK 93923826T DK 0663912 T3 DK0663912 T3 DK 0663912T3
Authority
DK
Denmark
Prior art keywords
ether compounds
heterocyclic ether
cognitive function
enhance cognitive
cholinergic
Prior art date
Application number
DK93923826T
Other languages
English (en)
Inventor
Melwyn A Abreo
David E Gunn
Nan-Horng Lin
Richard L Elliott
David S Garvey
Suzanne A Lebold
James T Wasicak
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of DK0663912T3 publication Critical patent/DK0663912T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK93923826T 1992-10-09 1993-10-08 Heterocykliske etherforbindelser til forstærkning af den kognitive funktion DK0663912T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95900592A 1992-10-09 1992-10-09
PCT/US1993/009662 WO1994008992A1 (en) 1992-10-09 1993-10-08 Heterocyclic ether compounds that enhance cognitive function

Publications (1)

Publication Number Publication Date
DK0663912T3 true DK0663912T3 (da) 2002-04-15

Family

ID=25501548

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93923826T DK0663912T3 (da) 1992-10-09 1993-10-08 Heterocykliske etherforbindelser til forstærkning af den kognitive funktion

Country Status (12)

Country Link
EP (1) EP0663912B1 (da)
JP (1) JP3098035B2 (da)
KR (1) KR100311546B1 (da)
AT (1) ATE210656T1 (da)
AU (1) AU687017B2 (da)
CA (1) CA2136075C (da)
DE (1) DE69331329T2 (da)
DK (1) DK0663912T3 (da)
ES (1) ES2169727T3 (da)
IL (1) IL107184A (da)
PT (1) PT663912E (da)
WO (1) WO1994008992A1 (da)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948793A (en) * 1992-10-09 1999-09-07 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5998404A (en) 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
IL118279A (en) * 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
WO1997017955A1 (en) * 1995-11-13 1997-05-22 Eli Lilly And Company Method for treating anxiety
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
US6979695B2 (en) 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US5629325A (en) * 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6437138B1 (en) 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6133253A (en) * 1996-12-10 2000-10-17 Abbott Laboratories 3-Pyridyl enantiomers and their use as analgesics
BR9714677A (pt) * 1996-12-10 2000-10-03 Abbott Lab "enantiÈmeros 3-piridila e seu uso como analgésicos"
CA2287223A1 (en) * 1997-04-26 1998-11-05 Tomohiro Toyoda 2-azabicyclo compounds
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6525065B1 (en) 1997-06-30 2003-02-25 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6624173B1 (en) 1997-06-30 2003-09-23 Targacept, Inc. Pharmaceutical compositions for treating and/or preventing CNS disorders
AU747419B2 (en) * 1997-11-05 2002-05-16 Neurosearch A/S Azaring-ether derivatives and their use as nicotinic ACH receptor modulators
CA2315117C (en) * 1997-12-19 2011-03-15 Abbott Laboratories Heterocyclic ether and thioether compounds useful in controlling chemical synaptic transmission
CA2317567A1 (en) * 1998-04-02 1999-10-14 R.J. Reynolds Tobacco Company Pharmaceutical compositions and methods for use
AU2880699A (en) 1998-04-02 1999-10-25 R.J. Reynolds Tobacco Company Pharmaceutical compositions and methods for use
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6432975B1 (en) * 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
AU5483500A (en) * 1999-07-09 2001-01-30 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
JP2003529547A (ja) * 1999-09-14 2003-10-07 アボット・ラボラトリーズ 化学シナプス伝達のコントロールに有効な３−ピロリジニルオキシ−３’−ピリジルエーテル化合物
US6890935B2 (en) 1999-11-01 2005-05-10 Targacept, Inc. Pharmaceutical compositions and methods for use
US6812314B2 (en) 2001-10-17 2004-11-02 University Of Florida Thermally responsive polymer materials and uses thereof
IL162153A0 (en) 2001-12-14 2005-11-20 Target Discovery Methods and compositions for treatment of central nervous systemdisorders
NZ551552A (en) 2002-07-05 2008-03-28 Targacept Inc N-Aryl diazaspirocyclic compounds capable of affecting nicotinic cholinergic receptors and methods of preparation and use thereof
AU2003254016A1 (en) 2002-07-19 2004-02-09 Catholic Healthcare West Methods and compositions relating to chimeric nicotinic receptor subunits
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
EP1678172B1 (en) 2003-10-15 2009-12-09 Targacept, Inc. Azabicyclic compounds for relieving pain and treating central nervous system disorders
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
CN101948462A (zh) 2004-09-20 2011-01-19 塔加西普特公司 具有烟碱性胆碱能受体活性的氮杂螺烯和氮杂螺烷化合物
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
CA2618700A1 (en) 2005-08-22 2007-03-01 Targacept, Inc. Heteroaryl-substituted diazatricycloalkanes, methods for its preparation and use thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
US8017785B2 (en) 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
TWI405763B (zh) 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
JP2010511014A (ja) * 2006-11-29 2010-04-08 ビーエーエスエフ ソシエタス・ヨーロピア 害虫を駆除するためのピリジン化合物
EP2112923A1 (en) 2007-01-22 2009-11-04 Targacept Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
TW200845977A (en) 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
US7718677B2 (en) 2007-04-02 2010-05-18 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009046025A1 (en) 2007-10-01 2009-04-09 Comentis, Inc. Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease
MX2011003306A (es) * 2008-10-14 2011-09-01 Psychogenics Inc Ligandos nicotinicos de receptor de acetilcolina y los usos de los mismos.
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
ES2820857T3 (es) 2008-12-01 2021-04-22 Oyster Point Pharma Inc Síntesis y formas de sal novedosas de (R)-5-((E)-2-pirrolidin-3-ilvinil)pirimidina
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
WO2011071758A1 (en) 2009-12-07 2011-06-16 Targacept, Inc. 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands
KR20130081221A (ko) 2010-05-20 2013-07-16 아스트라제네카 아베 아릴 치환된 올레핀계 아민의 신규 제조 방법
ES2623373T3 (es) 2010-05-27 2017-07-11 Catalyst Biosciences, Inc. Antagonistas no competitivos del receptor nicotínico
WO2012125518A1 (en) 2011-03-14 2012-09-20 Targacept, Inc. Salt forms of 3 - cyclopropylcarbonyl - 3, 6 - diazabicyclo [3.1.1] heptane
WO2012129262A1 (en) 2011-03-23 2012-09-27 Targacept, Inc. Treatment of attention deficit/hyperactivity disease
TW201311698A (zh) 2011-08-22 2013-03-16 Targacept Inc 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷
WO2013071097A1 (en) 2011-11-11 2013-05-16 Georgetown University 2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof
JP2017524736A (ja) 2014-07-11 2017-08-31 アルファーマゲン，エルエルシー アルファ７−ニコチン性アセチルコリン受容体活性を調節するためのキヌクリジン化合物
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
CN105418477B (zh) * 2015-12-22 2018-12-21 爱斯特（成都）生物制药股份有限公司 降低雷迪帕韦中间体中非对映异构体杂质含量的方法
JP2020503950A (ja) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 経皮薬剤送達の装置及び方法
AU2019279884A1 (en) 2018-05-29 2020-12-10 Morningside Venture Investments Limited Drug delivery methods and systems

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA848275B (en) * 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
CA1307790C (en) * 1987-08-04 1992-09-22 Ian Anthony Cliffe Ethers
YU84791A (sh) * 1990-05-19 1994-06-10 Boehringer Ingelheim Kg. Biciklicni 1-aza-cikloalkalni

Also Published As

Publication number Publication date
CA2136075A1 (en) 1994-04-28
EP0663912A4 (en) 1995-02-17
JP3098035B2 (ja) 2000-10-10
PT663912E (pt) 2002-06-28
AU5355794A (en) 1994-05-09
DE69331329T2 (de) 2002-08-08
KR100311546B1 (ko) 2005-12-06
EP0663912B1 (en) 2001-12-12
AU687017B2 (en) 1998-02-19
ATE210656T1 (de) 2001-12-15
KR950701920A (ko) 1995-05-17
CA2136075C (en) 2004-12-14
ES2169727T3 (es) 2002-07-16
DE69331329D1 (de) 2002-01-24
IL107184A (en) 1997-08-14
IL107184A0 (en) 1994-01-25
WO1994008992A1 (en) 1994-04-28
EP0663912A1 (en) 1995-07-26
JPH08502481A (ja) 1996-03-19

Similar Documents

Publication Publication Date Title
DK0663912T3 (da) Heterocykliske etherforbindelser til forstærkning af den kognitive funktion
FI931888A (fi) Kramploesande cykliska fruktopyranossulfiter -och sulfater
ATE273296T1 (de) 3-pyridyloxymethyl heterocyclische ether verbindungen für die kontrolle chemischer synaptischer übertragung
ZA842185B (en) New n-aryl-n'-cycloalkylalkanoyl-piperazine and process for the production thereof
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
DE69505470T2 (de) Pyrrolocarbazol
TW429255B (en) Pyrazine compounds having treatment of central nervous system diseases and disorders
DE69933885D1 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen
PT1049672E (pt) Derivados de azetidinocarboxamida para o tratamento de disturbios do snc
DK0623131T3 (da) Alkylderivater af trazodon med CNS-aktivitet
DK52383D0 (da) Fremgangsmade til fremstilling af carbacyklinderivater
DK0784973T3 (da) Quinoxalinderivater til behandling af tinnitus
DK1049670T3 (da) Azetidincarboxamidderivater til behandling af CNS-lidelser
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders
MA20461A1 (fr) Procede de preparation de nouveaux derives de l'isoxazoloquinoleine
ES8701144A1 (es) Un procedimiento para preparar un derivado de tetrahidronaf-taleno
ATE28628T1 (de) Phenylethylaminderivate und ihre zwischenprodukte.
YU49004B (sh) LANOSTA-7,9-DIEN-3Гџ, 32-DIOL I POSTUPAK ZA NJEGOVO DOBIJANJE
FR2401136A1 (fr) Derives de type isothio-uree